If you have been diagnosed with anemia from myeloproliferative neoplasm–associated (MPN-associated) myelofibrosis (MF), you may be eligible to take part in a clinical research study.
Study Purpose:
The INDEPENDENCE Trial is seeking to determine if people with MPN-associated MF who need red blood cell (RBC) transfusions will stop needing transfusions or require less frequent RBC transfusions by taking luspatercept (ACE-536). This study is also evaluating the safety of luspatercept.
All individuals who qualify and enroll will receive either luspatercept or a placebo, as well as study-related exams and study-related laboratory tests, at no cost. The total length of participation is approximately five years.
Eligibility Criteria:
Eligible participants must:
- Be 18 years of age or older
- Have a confirmed diagnosis of primary myelofibrosis (PMF), post-essential thrombocythemia MF (post-ET MF), or post-polycythemia vera MF (post-PV MF)
- Require RBC transfusions given for the treatment of anemia
- Be on a continuous and stable dose of JAK2 inhibitor therapy
Other protocol-defined inclusion and exclusion criteria apply.
A special website has been created to provide more information about the INDEPENDENCE Trial.
CLICK HERE for more information.